Alto Neuroscience (ANRO) Net Cash Flow (2023 - 2026)
Alto Neuroscience (ANRO) posted Net Cash Flow of $87.3 million for Q1 2026, up 125.75% sequentially from $38.7 million in Q4 2025, and up 1271.26% YoY from $6.4 million in Q1 2025.
Alto Neuroscience (ANRO) Net Cash Flow (2023 - 2026) Analysis & Trends
Alto Neuroscience has reported Net Cash Flow for 4 years, with the latest figure at $87.3 million in Q1 2026.
- Quarterly Net Cash Flow rose 1271.26% year-over-year to $87.3 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $103.0 million (up 330.95% YoY) and the FY2025 annual result came in at $8.3 million, down 90.39% from the prior year.
- Net Cash Flow improved to $87.3 million in Q1 2026 per ANRO's latest filing, from $38.7 million in the prior quarter.
- Over five years, Net Cash Flow peaked at $123.4 million in Q1 2024 and troughed at -$13.5 million in Q4 2024.
- A 4-year average of $16.6 million and a median of -$7.5 million in 2025 frame the typical range for Net Cash Flow.
- The sharpest annual moves came in 2024 and 2026: Net Cash Flow tumbled 143.12% in 2024, then soared 1271.26% in 2026.
- Over 4 years, Net Cash Flow stood at $31.3 million in 2023, then sank by 143.12% to -$13.5 million in 2024, then jumped by 386.9% to $38.7 million in 2025, then jumped by 125.75% to $87.3 million in 2026.
- According to Business Quant data, Net Cash Flow over the past three periods registered $87.3 million, $38.7 million, and -$9.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 652.90 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | -504.30 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 374.50 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 407.41 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 17.81 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 225.59 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | -496,000.00 |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -37.14 Mn |
| 10 | Alto Neuroscience | 1.13 Bn | 1.13 Bn | - | -20.03 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -20.03 Mn |
| Jun 30, 2026 | -20.03 Mn |
| Mar 31, 2026 | 87.29 Mn |
| Mar 31, 2026 | 87.29 Mn |
| Dec 31, 2025 | 38.67 Mn |
| Dec 31, 2025 | 38.67 Mn |
| Sep 30, 2025 | -9.77 Mn |
| Sep 30, 2025 | -9.77 Mn |
| Jun 30, 2025 | -13.17 Mn |
| Jun 30, 2025 | -13.17 Mn |
| Mar 31, 2025 | -7.45 Mn |
| Mar 31, 2025 | -7.45 Mn |
| Dec 31, 2024 | -13.48 Mn |
| Dec 31, 2024 | -13.48 Mn |
| Sep 30, 2024 | -11.41 Mn |
| Sep 30, 2024 | -11.41 Mn |
| Jun 30, 2024 | -12.27 Mn |
| Jun 30, 2024 | -12.27 Mn |
| Mar 31, 2024 | 123.35 Mn |
| Mar 31, 2024 | 123.35 Mn |